Word on the street is that Moderna is developing a **skin cancer vaccine** to be released by 2025. While the company's **mRNA solid tumour vaccine** shows early promise, there's opposition amidst Florida's surgeon general cautioning against mRNA COVID-19 vaccines. Recent times haven't been the best for Moderna, with plunging stock prices attributed to diminishing COVID-19 vaccine sales and reduced R&D plans. The necessary culling of five programmes to save $1.1bn is indicative of frugality, while an emerging Mpox vaccine presents hope in the combat against this disease. Amid concerns about waning internal confidence and plummeting stock prices, there's a glimmer of positivity with the U.S. government's choice to spend $176m on Moderna's bird flu vaccine development. Anticipated backlash is reported over the company's slashed R&D budget and lukewarm vaccine sales. There's hope that Moderna could revolutionize cancer research with a radical adaptability approach for mRNA. Their **first vaccine** was well received, with hopes the second can replicate that success. Meanwhile, tensions rise as Pfizer's patent battle continues, and Moderna has halted Kenyan plant plans due to reported financial setbacks. Moderna's R&D budget cut controversy is exacerbated as they continue negotiations with the **U.S. government**.
Moderna MRNA News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Sun, 15 Sep 2024 15:30:00 GMT -
Rating -6
- Innovation 4
- Information 6
- Rumor -2
